Loading
Nobody has directly compared an off-the-shelf bispecific with CAR-T in the same patients; a trial would settle where each belongs.
The idea is a head-to-head randomised trial of an off-the-shelf CD20 bispecific, epcoritamab or glofitamab with chemotherapy, against the CAR-T product axicabtagene ciloleucel in second-line large B-cell lymphoma. CAR-T has phase 3 event-free and overall survival wins in early relapse, while bispecifics have single-arm data and one mixed phase 3 in EPCORE DLBCL-1, but can be repeated, arrive within a week, and win on access and cost. The hypothesis is that a bispecific with chemotherapy is non-inferior to axi-cel on event-free survival at lower cost with comparable cytokine release syndrome. The test is a randomised non-inferiority trial with quality of life and cost as secondary endpoints; the speculative idea addresses the manufacturing bottleneck.
One of the most cited trial reports Europe PMC returns for Glofitamab in Diffuse large B-cell lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for Glofitamab in Diffuse large B-cell lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
ZUMA-1 showed that CAR-T can cure a meaningful fraction of adults whose aggressive lymphoma no longer responds to chemotherapy, a group with a historical median survival of about six months (SCHOLAR-1). Axi-cel became the first CAR-T approved for lymphoma and later the first to beat standard second-line therapy in ZUMA-7. The comparatively high neurotoxicity of CD28-costimulated products was also first characterised here.
Shares Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Glofitamab, T-cell engagers (bispecific).
Shares ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma, Axicabtagene ciloleucel, CAR-T cell therapy, Diffuse large B-cell lymphoma.
Shares Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial, Glofitamab, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
Shares ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma, Axicabtagene ciloleucel, CAR-T cell therapy, Diffuse large B-cell lymphoma.
Shares Epcoritamab, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
Shares Epcoritamab, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
Shares Epcoritamab, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
Shares Axicabtagene ciloleucel, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.